This review outlines positron emission tomography (PET) biomarkers used in Alzheimer's disease (AD) research and clinical settings, targeting both specific (amyloid, tau) and non‐specific (neurodegeneration, synaptic density, neuroinflammation) processes. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.